Engineering immune cells to fight leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how to make a patient's own immune cells better at attacking leukemia. It uses samples from patients and healthy donors to develop a new way to boost the body's defense against cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must be willing to sign a consent form to use your blood or bone marrow samples for research.
- If you are a patient, you must have a diagnosis of acute myeloid leukemia (AML).
- If you are a healthy donor, you must be donating stem cells for a transplant, and your samples must be stored in the San Raffaele biobank.
- You must have a specific genetic marker (HLA type) that the study is looking for.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cancer treatment made from a close family member’s immune cells, adjusted in the lab and given to children or young adults with AML. It may help the immune system better attack leukemia, especially for high-risk, relapsed, or refractory AML.
This study tests an “immune cell therapy” made from a family donor to help children and young adults with AML stay in remission after chemotherapy. It may help reduce the chance that AML comes back, but eligibility depends on remission status, donor suitability, and avoiding certain infections or liver issues.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests a stem cell transplant from a partially matched family member combined with donor immune cells and targeted drugs for acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to help patients who have few other options.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This study is looking at blood and bone marrow samples from people with acute leukemia to understand how the immune system reacts to the disease and treatment. The goal is to find better ways to treat leukemia.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.